Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial

Abstract Objective The effectiveness and security of radiofrequency ablation (RFA) in combination with toripalimab (anti‐PD‐1) for the treatment of recurrent hepatocellular carcinoma (HCC) was studied in this article. Methods Total of 40 patients were enrolled in the study between September 2019 and...

Full description

Bibliographic Details
Main Authors: Zhenyu Wen, Junxiao Wang, Bo Tu, Yane Liu, Yuqing Yang, Li Hou, Xiang Yang, Xiaoyan Liu, Hui Xie
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Cancer Medicine
Subjects:
anti‐PD‐1
prospective study
radiofrequency ablation
recurrent hepatocellular carcinoma
toripalimab
Online Access:https://doi.org/10.1002/cam4.6602

Similar Items

Similar Items